Arbele is positioned to be a leader in cancer immunotherapies for solid tumors. A central player in cancer immunotherapy is a type of white blood cell known as the T cell. In healthy individuals, T cells identify and kill infected or abnormal cells like tumors. However, cancer cells carrying the ability (especially in solid tumors) to evade immune surveillance is a key factor in their growth, spread, and persistence. We leverage two technologies - Chimeric Antigen Receptor (CAR) and Bi-specific Monoclonal Antibodies (BiMAbs) - to activate the patient's T cells so that they attack cancer cells.
Through genetic engineering we express a tumor-specific CAR in patient T cells which enables them to specifically recognize and kill cancer cells. Our next-gen CAR technology (in proof-of concept stage) that directs T cells infiltrating into a solid tumor microenvironment to kill cancer cells (while remaining "quiescent" in normal healthy tissues) will enable high efficacy and minimize side effects. Furthermore, we are developing a novel-CAR vector in the next 2-3 years, having scalable capability at GMP/PICS manufacturing facilities. Capitalizing our expertise around antibody engineering, we are replacing a humanized antibody platform to a "fully human" scFv for our CAR and Bi-specific antibody biologics. Our priority tumor target CDH17 is protected by our patent for liver cancer worldwide. In addition, CDH17 is also highly expressed in stomach as well as metastatic colon and other cancer types. Long-term development includes building an end-to-end pipeline fueled by technology platforms. Next-Gen Sequencing (NGS) of circulating tumor DNA for early cancer detection and data mining based on tumor biopsies will be directed toward precision eMedicine in 2020.
Chimeric Antigen Receptor (CAR) technology directs T and NK (natural killer) cells to recognize cancer cells based on expression of specific cell surface proteins.Learn More
The use of bispecific antibodies, targeting two tumor antigens for cancer treatment. This approach evolves to BiTE therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death.Learn More
Using high-throughput and cutting-edge DNA sequencing technology, we can identify the oncogenes and mutations unique in patient's samples - tumor and liquid biopsies for early diagnosis and precision treatments.Learn More